1.1Antibody capture of interferon
The antigen-binding fragment recognizes a surface on soluble interferon-γ that overlaps its receptor-binding site. Occupancy of that site reduces activation of cell-surface interferon-γ receptors.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The antigen-binding fragment recognizes a surface on soluble interferon-γ that overlaps its receptor-binding site. Occupancy of that site reduces activation of cell-surface interferon-γ receptors.
The extracellular domain of the interferon-γ receptor alpha chain is fused to an antibody constant region that supports dimer formation. The soluble dimer binds interferon-γ and reduces the amount of free cytokine available to activate receptors on ocular surface cells.
The oligonucleotide hybridizes to a complementary segment of the receptor transcript inside ocular surface cells. Ribonuclease H cleaves the RNA strand of the hybrid, reducing receptor expression and cellular responsiveness to interferon-γ.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A porous cartridge holds agarose beads bearing the IFN-γ-binding DNA oligonucleotide tethered through a terminal spacer. Conditioned medium from a mammalian cell culture passes through the bead bed, where immobilized oligonucleotides capture soluble IFN-γ. The cartridge outlet feeds a collection vessel, and measurements of IFN-γ in inlet and outlet samples track capture performance.
A neutralizing anti-IFN-γ antigen-binding fragment replaces the DNA oligonucleotide as the active ingredient. A sterile, buffered isotonic solution carries the fragment in a single-use ophthalmic vial. After topical instillation, the fragment binds soluble IFN-γ at the ocular surface and blocks its interaction with the receptor.
A positive-displacement dispenser delivers the DNA oligonucleotide formulation to a corneal epithelial culture under a flowing artificial tear film. The test compares aliquots of 5, 10, and 20 microliters at the same oligonucleotide concentration. Outlet samples collected at 1, 5, and 15 minutes provide measurements of free IFN-γ and recovered oligonucleotide for each volume.
A soft hydrogel contact lens incorporates an annular reservoir filled with a solution of the IFN-γ-binding DNA oligonucleotide. A hydrophilic membrane covers the reservoir on the tear-facing surface, and the central optical zone remains clear. The oligonucleotide diffuses through the membrane into the tear film, where it binds soluble IFN-γ.
A single-use ophthalmic dispenser holds a freeze-dried DNA oligonucleotide formulation in one chamber and sterile buffered diluent in a second chamber. Pressing the actuator opens an internal seal and transfers the diluent into the chamber containing the dried formulation. After reconstitution, the solution passes through a drop-forming tip for topical application.
A programmable liquid handler dispenses fresh and stored samples of the DNA oligonucleotide formulation into a multiwell plate and adds a fixed amount of IFN-γ to each well. The instrument transfers the mixtures to wells coated with the extracellular domain of the IFN-γ receptor and measures receptor-bound cytokine using a labeled detection antibody. Software compares the signals with cytokine-only and fresh-formulation controls and reports retained inhibition of receptor binding for each stored sample.
A single-stranded DNA oligonucleotide uses the nucleotide order specified by SEQ ID NO:1. A binding assay measures interaction with interferon-γ and uses an unrelated cytokine as a specificity control.
The DNA oligonucleotide uses the nucleotide order specified by SEQ ID NO:3 and carries a polyethylene glycol chain covalently attached at artificial base X. A binding assay measures selective interaction with interferon-γ after conjugation.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A sialic acid recognition DNA oligonucleotide aptamer molecule(s) as claimed in claim 1 which are for either anti-Neu5Gc or anti-Neu5Ac selected from the following sequences: anti-Neu5Gc DNA oligonucleotide aptamer molecule(s): (16) 5′-CGCGCGCAACAATACACACAACCTTCGCGTTCRG-3′, where R is either G or A: anti-Neu5Ac DNA oligonucleotide aptamer molecule(s): (17): 5′-CGCGCCCACATTTAGACCCCAACCTTCGCGGCTTG-3′, or (18): 5′-CGCGCCAACAACACCACCAATCTTCGCAGCCCG -3′, or (19): 5′-CGCGCGCAACAATAA · US 2020/0072821 A1 · claim 8
The recognition element comprises a DNA polymerase enzyme, a DNA polymerase enzyme-specific DNA aptamer and an inverter oligonucleotide.B · US 2021/0130870 A1 · abstract
An empty cell means only that no passage was reproduced there.
In particular, the invention provides recognition molecules (protein and nucleic acid based), for application in the detection, measurement and discrimination of the sialic acid forms N-glycolylneuraminic acid (Neu5Gc) and N-acetylneuraminic acid (Neu5Ac) when presented as either bound (biological or chemical molecule presented) or free form available in suspension.A · US 2020/0072821 A1 · ¶ 1
Though lectins from plant and animal sources recognize sialic acids, subject to presentation, their use for in vitro assays are greatly limited due to their poor stability, low sensitivity and cross reactivity with different forms and presentation of sialic acids making it impossible to explicitly discriminate between Neu5Ac and Neu5Gc in such a manner that would be useful for commercial application.A · US 2020/0072821 A1 · ¶ 6
There is a need for a molecular platform to enable rapid, visual and modular detection of nucleic acids.B · US 2021/0130870 A1 · ¶ 4
Instead of relying on target nucleic acid amplification, the technology of the present invention exponentially enhances visual signal from direct and independent target hybridization.B · US 2021/0130870 A1 · ¶ 5
patent.fyi, US 2026/0355326 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355326/, SHA-256 7bee62d9907bf9f74f34d8e5894484fbac742236c2116dd52b743778c4aff366